Related Experiment Video
Updated: Apr 3, 2026
06:15
Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
Published on: November 10, 2023
1.5K
Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial
D Ruttens1, S E Verleden1, E Vandermeulen1
1Lung Transplant Unit, Division of Respiratory Diseases, Department of Clinical and Experimental Medicine, KULeuven and UZ Leuven, Leuven, Belgium.
Summary
Prophylactic azithromycin significantly reduces chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx). This treatment improves long-term survival, pulmonary function, and exercise capacity, offering better outcomes for transplant recipients.
Area of Science:
- Transplantation immunology
- Pulmonology
- Pharmacology
Background:
- Bronchiolitis obliterans syndrome (BOS), now classified under chronic lung allograft dysfunction (CLAD), is a major complication after lung transplantation (LTx).
- Previous studies suggested prophylactic azithromycin improves early outcomes, but long-term effects require re-evaluation with updated CLAD criteria.
Purpose of the Study:
- To assess the long-term efficacy of prophylactic azithromycin in preventing CLAD and improving post-LTx outcomes.
- To analyze the impact of azithromycin on CLAD-free survival, graft loss, pulmonary function, and exercise capacity up to 7 years post-LTx.
Main Methods:
- Retrospective analysis of a randomized controlled trial comparing azithromycin versus placebo in LTx patients.
- Intention-to-treat analysis evaluating CLAD development, graft loss, pulmonary function, and functional exercise capacity.
Main Results:
- Significantly lower incidence of CLAD in the azithromycin group (28%) compared to placebo (51%) (p=0.043).
- Improved CLAD-free survival in patients receiving azithromycin (p=0.024).
- Enhanced long-term pulmonary function and functional exercise capacity in the azithromycin group (p<0.05).
Conclusions:
- Prophylactic azithromycin therapy is effective in reducing long-term CLAD prevalence after LTx.
- Azithromycin improves CLAD-free survival, pulmonary function, and functional exercise capacity, supporting its use in post-lung transplant care.
